Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Elena Cavalieri"'
Autor:
Maria Cristina Bonferoni, Luca Ferraro, Barbara Pavan, Sarah Beggiato, Elena Cavalieri, Paolo Giunchedi, Alessandro Dalpiaz
Publikováno v:
Pharmaceutics, Vol 11, Iss 3, p 106 (2019)
The pharmacological activities of geraniol include anticancer and neuroprotective properties. However, its insolubility in water easily induces separation from aqueous formulations, causing administration difficulties. Here we propose new emulsified
Externí odkaz:
https://doaj.org/article/bf7b1bcdd2bb47ccb464eb48fd89d811
Autor:
Gabriella Parisi, Lucia Palombi, Rosario Andrea Cocchiara, Linda Cerbone, Elena Cavalieri, Bruno Mariani, Daniela Iacono, Carlo Garufi, Isabella Sperduti
Publikováno v:
Journal of Geriatric Oncology
Central studies carried out on vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-COV2) excluded patients receiving immunosuppressive therapy and those diagnosed with an immunosuppressive condition. Moreover, there are no data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12470498894e09dcd7be74b609279d65
https://pubmed.ncbi.nlm.nih.gov/34175246
https://pubmed.ncbi.nlm.nih.gov/34175246
Autor:
Sarah Beggiato, Luca Ferraro, Barbara Pavan, Elena Cavalieri, Alessandro Dalpiaz, Maria Cristina Bonferoni, Paolo Giunchedi
Publikováno v:
Pharmaceutics
Volume 11
Issue 3
Pharmaceutics, Vol 11, Iss 3, p 106 (2019)
Volume 11
Issue 3
Pharmaceutics, Vol 11, Iss 3, p 106 (2019)
The pharmacological activities of geraniol include anticancer and neuroprotective properties. However, its insolubility in water easily induces separation from aqueous formulations, causing administration difficulties. Here we propose new emulsified
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::715d1b210d331c989f5a937384f288cc
http://hdl.handle.net/11392/2403972
http://hdl.handle.net/11392/2403972
Autor:
Armando Bartolazzi, Roberto Becelli, Luigi Ruco, Arianna Di Napoli, Elena Cavalieri, Claudia Cippitelli, Giuseppe Mallel
Publikováno v:
International Journal of Surgical Pathology. 23:419-423
Hodgkin lymphoma (HL) associated with Warthin tumor (WT) is extremely rare, accounting for only 3 cases of classical HLs. Here, we report for the first time the occurrence of a nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) involving the lym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7c10df929d313e12d93760b11c14208
https://doi.org/10.1177/1066896915582263
https://doi.org/10.1177/1066896915582263
Autor:
Alessandro Pulsoni, Vitaliana De Sanctis, Giorgia Annechini, Maurizio Valeriani, Marco Alfò, Francesco Romeo Filippone, Mattia Falchetto Osti, Riccardo Maurizi Enrici, Roberta Muni, Giuseppe Minniti, Elena Cavalieri
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 84:755-761
Purpose The aim of this study was to evaluate the pregnancy outcomes in women with Hodgkin lymphoma (HL) diagnosis, treated between 1972 and 1999 at Department of Radiotherapy and Hematology of University “Sapienza” of Roma. Methods and Materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c80d1ebc16f62a4bf4eee8c87103cde7
https://doi.org/10.1016/j.ijrobp.2011.12.066
https://doi.org/10.1016/j.ijrobp.2011.12.066
Autor:
Vittorio Stefoni, Stefano Pileri, Francesco Scopinaro, Stefano Fanti, Alessandro Broccoli, Giancarlo Montini, Monica Tani, Fabio Torelli, Enrico Derenzini, Letizia Gandolfi, Alessandro Pulsoni, A De Renzo, Michele Baccarani, Lisa Argnani, Federica Quirini, Mariapaola Fina, Pier Luigi Zinzani, Cinzia Pellegrini, Martina Rossi, Elena Cavalieri
Publikováno v:
Annals of Oncology. 23:415-420
Background A prospective, single-arm, open-label, multicenter, nonrandomised phase II trial to evaluate efficacy and safety of short fludarabine, mitoxantrone, and rituximab (FMR) induction followed by radioimmunotherapy, in untreated, intermediate/h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc2f1d970b88e488f4c22c30bab7946
https://doi.org/10.1093/annonc/mdr145
https://doi.org/10.1093/annonc/mdr145
Autor:
Angela Matturro, Robin Foà, Lavinia Grapulin, Federico De Angelis, Elena Cavalieri, Alessandro Pulsoni, Marco Vignetti, Fabiana Gentilini, Mikael Sacco, Fabio Torelli, Giorgia Annechini, Franco Mandelli, Natalia Frattarelli
Publikováno v:
Leukemia & Lymphoma. 50:1803-1808
The BEACOPP regimen is a consolidated first-line treatment regimen for advanced stage Hodgkin lymphoma (HL), while few data are available on the efficacy of this regimen in advanced disease. About 50% of patients with HL relapsed after or refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d204599a03b251294e6cee219a1da01
https://doi.org/10.3109/10428190903254383
https://doi.org/10.3109/10428190903254383
Autor:
Vincenzo Pavone, Corrado Schiavotto, Elena Cavalieri, Michele Spina, Gian Matteo Rigolin, Stefano Molica, Antonello Pinto, Anna Marina Liberati, Stefano Volpetti, Luigi Rigacci, Giuseppe Gritti, Monica Tani, Patrizio Mazza, Paolo Corradini, Alessandra Romano, Pellegrino Musto, Maurizio Bonfichi, Stefan Hohaus, Chiara Rusconi, Guido Gini, Patrizia Tosi, Pier Luigi Zinzani, Lisa Argnani, Alessandro Broccoli, Angelo Michele Carella, Fioravante Ronconi, Donato Mannina, Filippo Gherlinzoni, Alessandro Pulsoni, Daniele Vallisa, Amalia De Renzo, Michele Merli, Andrea Visentin, Barbara Botto, Maria Goldaniga, Anna Vanazzi, Caterina Patti, Armando Santoro, Francesco Gaudio, Angelo Fama
Publikováno v:
Blood. 128:4161-4161
From November 2012 to July 2014, brentuximab vedotin (BV) was available in Italy for patients with relapsed Hodgkin's lymphoma (HL) outside a clinical trial context based on a local disposition of the Italian Drug Agency (AIFA) issued according to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf81ed8f288244dcfaf096903486fe41
https://doi.org/10.1182/blood.v128.22.4161.4161
https://doi.org/10.1182/blood.v128.22.4161.4161
Autor:
Franco Mandelli, Elena Cavalieri, R. Maurizi Enrici, Anselmo Ap, Giovanna Meloni, D. Funaro, Anna Proia, Edoardo Pescarmona
Publikováno v:
Annals of Hematology. 79:79-82
Despite progress that has been made in curing Hodgkin's disease (HD), patients whose first remission is brief and those resistant to first-line chemotherapy still have a poor outcome. We retrospectively reviewed data from 29 patients with HD in first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a11710aaa8faddd35432adab533c895f
https://doi.org/10.1007/s002770050014
https://doi.org/10.1007/s002770050014